Acceleron Pharma Inc. (NASDAQ:XLRN) – Investment analysts at Oppenheimer Holdings upped their Q3 2017 earnings estimates for Acceleron Pharma in a research note issued to investors on Thursday. Oppenheimer Holdings analyst L. Cann now forecasts that the biopharmaceutical company will earn ($0.63) per share for the quarter, up from their previous forecast of ($0.67). Oppenheimer Holdings has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Acceleron Pharma’s Q4 2017 earnings at ($0.53) EPS, FY2017 earnings at ($2.57) EPS, Q1 2018 earnings at ($0.56) EPS, Q2 2018 earnings at ($0.57) EPS, Q3 2018 earnings at ($0.56) EPS, Q4 2018 earnings at ($0.55) EPS, FY2018 earnings at ($2.24) EPS, FY2019 earnings at ($2.32) EPS, FY2020 earnings at ($1.89) EPS and FY2021 earnings at ($0.30) EPS.

Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.12). The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.69 million. Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. Acceleron Pharma’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.59) earnings per share. COPYRIGHT VIOLATION WARNING: “Acceleron Pharma Inc. Expected to Post Q3 2017 Earnings of ($0.63) Per Share (XLRN)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/10/acceleron-pharma-inc-expected-to-post-q3-2017-earnings-of-0-63-per-share-xlrn.html.

Several other research analysts have also recently weighed in on XLRN. Cann restated a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. CIBC cut Acceleron Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 13th. Morgan Stanley decreased their price target on Acceleron Pharma from $51.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, June 13th. FBR & Co set a $63.00 price target on Acceleron Pharma and gave the stock a “buy” rating in a research note on Tuesday, June 13th. Finally, Instinet restated a “buy” rating and issued a $58.00 price target on shares of Acceleron Pharma in a research note on Wednesday, June 14th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Acceleron Pharma presently has a consensus rating of “Buy” and a consensus target price of $42.81.

Shares of Acceleron Pharma (NASDAQ:XLRN) opened at 38.78 on Monday. The stock’s market capitalization is $1.50 billion. Acceleron Pharma has a 52-week low of $23.07 and a 52-week high of $41.69. The company has a 50-day moving average price of $37.15 and a 200-day moving average price of $31.91.

In related news, SVP John D. Quisel sold 5,113 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $38.42, for a total transaction of $196,441.46. Following the completion of the sale, the senior vice president now owns 57,918 shares in the company, valued at $2,225,209.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Corp /De/ Celgene acquired 745,592 shares of Acceleron Pharma stock in a transaction that occurred on Monday, September 25th. The shares were purchased at an average price of $37.00 per share, with a total value of $27,586,904.00. Following the transaction, the insider now owns 6,118,479 shares of the company’s stock, valued at approximately $226,383,723. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 66,578 shares of company stock valued at $2,518,117. 3.90% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Birchview Capital LP purchased a new stake in Acceleron Pharma during the second quarter valued at $456,000. AXA bought a new stake in Acceleron Pharma during the second quarter valued at about $9,833,000. Teachers Advisors LLC grew its holdings in Acceleron Pharma by 2.1% during the first quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock valued at $1,220,000 after purchasing an additional 942 shares during the period. TD Asset Management Inc. grew its holdings in Acceleron Pharma by 0.8% during the second quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock valued at $2,395,000 after purchasing an additional 600 shares during the period. Finally, Weiss Multi Strategy Advisers LLC grew its holdings in Acceleron Pharma by 33.3% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 20,000 shares of the biopharmaceutical company’s stock valued at $529,000 after purchasing an additional 5,000 shares during the period. Institutional investors own 77.35% of the company’s stock.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Earnings History and Estimates for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.